Fate Therapeutics Advances FT819 in Lupus Nephritis
San Diego, California — August 14, 2026 Fate Therapeutics, Inc. has initiated the potentially registrational RECLAIM-LN Phase 2 clinical...
IPSC
Advertisement
NueCell Bio Launches GMP Cell Therapy Development Platform
San Diego, California, August 5, 2026 NueCell Bio has officially launched as a specialized cell therapy science and development...
Century Therapeutics Showcases CNTY-813 at EASD
PHILADELPHIA, July 9, 2026 Century Therapeutics announced that its CNTY-813 preclinical research has been selected for oral presentations at...
RoosterBio and Applied StemCell Partner to Scale iPSC Manufacturing
MILPITAS, Calif. & FREDERICK, Md., July 8, 2026 RoosterBio and Applied StemCell (ASC) have announced a strategic partnership to...
Fate Therapeutics to Present FT819 Data at ISSCR 2026
SAN DIEGO, July 6, 2026 Fate Therapeutics announced that preliminary clinical data from its investigational FT819 off-the-shelf CD19-targeting CAR...
Advertisements
Kenai Therapeutics Completes Phase 1b/2a REPLACE Trial Enrollment
SAN DIEGO, July 7, 2026 Kenai Therapeutics has announced the successful completion of patient enrollment in the Phase 1b/2a...
United Therapeutics Expands Cell Therapy with Thymmune Deal
SILVER SPRING, Maryland & RESEARCH TRIANGLE PARK, North Carolina, July 2, 2026 United Therapeutics Corporation has announced the acquisition...
Aspen Neuroscience Completes Cohort 4 in ASPIRO Parkinson’s Trial
SAN DIEGO, June 30, 2026 Aspen Neuroscience, Inc. has announced the successful completion of Cohort 3 and Cohort 4...
Syntax Bio Teams Up with Mayo Clinic to Advance Diabetes Treatment
CHICAGO, June 10, 2026 Syntax Bio announced a research and development collaboration with Mayo Clinic to accelerate the development...
TreeFrog’s TFG-001 Shows Strong Parkinson’s Recovery Data
BORDEAUX, France, May 25, 2026 TreeFrog Therapeutics announced new preclinical data showing that its investigational 3D neural microtissue cell...
Advertisement
